These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections. Li XM, Hedlund PB, Fuxe K. Eur J Neurosci; 1995 May 01; 7(5):962-71. PubMed ID: 7613631 [Abstract] [Full Text] [Related]
5. Regulation of dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells cotransfected with human CCKB and D2L receptor cDNAs. Dasgupta S, Li XM, Jansson A, Finnman UB, Matsui T, Rinken A, Arenas E, Agnati LF, Fuxe K. Brain Res Mol Brain Res; 1996 Mar 01; 36(2):292-9. PubMed ID: 8965650 [Abstract] [Full Text] [Related]
6. The C-terminal neurotensin-(8-13) fragment potently modulates rat neostriatal dopamine D2 receptors. Li XM, Von Euler G, Hedlund PB, Finnman UB, Fuxe K. Eur J Pharmacol; 1993 Mar 30; 234(1):125-8. PubMed ID: 8472756 [Abstract] [Full Text] [Related]
7. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Tanganelli S, Li XM, Ferraro L, Von Euler G, O'Connor WT, Bianchi C, Beani L, Fuxe K. Eur J Pharmacol; 1993 Jan 12; 230(2):159-66. PubMed ID: 8422898 [Abstract] [Full Text] [Related]
8. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Proc Natl Acad Sci U S A; 1991 Aug 15; 88(16):7238-41. PubMed ID: 1678519 [Abstract] [Full Text] [Related]
9. A single (-)-nicotine injection causes change with a time delay in the affinity of striatal D2 receptors for antagonist, but not for agonist, nor in the D2 receptor mRNA levels in the rat substantia nigra. Li XM, Zoli M, Finnman UB, Le Novère N, Changeux JP, Fuxe K. Brain Res; 1995 May 08; 679(1):157-67. PubMed ID: 7648259 [Abstract] [Full Text] [Related]
16. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, Laruelle M. Synapse; 2004 Jun 01; 52(3):188-208. PubMed ID: 15065219 [Abstract] [Full Text] [Related]
17. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA. Neuropsychopharmacology; 2003 Jan 01; 28(1):108-18. PubMed ID: 12496946 [Abstract] [Full Text] [Related]
18. Coactivation of dopamine D1 and D2 receptors increases the affinity of cholecystokinin-8 receptors in membranes from post-mortem human caudate-putamen. von Euler G, Mailleux P, von Euler M, Schiffmann SN, Vanderhaeghen JJ, Fuxe K. Brain Res; 1992 Jul 03; 584(1-2):157-62. PubMed ID: 1325243 [Abstract] [Full Text] [Related]
19. Comparative biochemical pharmacology of central nervous system dopamine D1 and D2 receptors. Reader TA, Molina-Holgado E, Dewar KM. Mol Neurobiol; 1992 Jul 03; 6(4):425-50. PubMed ID: 1285933 [Abstract] [Full Text] [Related]
20. The excitatory effect of cholecystokinin on rat neostriatal neurons: ionic and molecular mechanisms. Wu T, Wang HL. Eur J Pharmacol; 1996 Jun 27; 307(2):125-32. PubMed ID: 8832213 [Abstract] [Full Text] [Related] Page: [Next] [New Search]